Apple Restores Telegram to App Store After Content Policy Violation 
FleetPartners Shares Jump After A$760 Million Takeover Proposal From Pacific Equity Partners 
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip 
Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
ATLANTA, March 23, 2018 -- GeoVax Labs, Inc. (OTCQB:GOVX), a biotechnology company developing innovative human vaccines using its novel platform technology, today announced its financial results for the year ended December 31, 2017.
GeoVax reported grant and collaboration revenues of $1.1 million for 2017, as compared to $0.8 million in 2016. Research and development (R&D) expenses were $2.0 million in 2017, compared with $2.0 million in 2016. General and administrative (G&A) expenses were $1.2 million in 2017, compared to $2.1 million in 2016.
Net loss for the year ended December 31, 2017 of $2.2 million, or $0.03 per share, based on 68.6 million weighted average shares outstanding. For the year ended December 31, 2016, the Company reported a loss of $3.3 million, or $0.08 per share, based on 41.5 million weighted average shares outstanding.
Robert McNally, PhD, President and CEO, commented, “During the past year, GeoVax made solid progress with its HIV human clinical program, built on its proof-of-concept in animal models for HIV, Zika, Ebola and Lassa vaccines, expanded its infectious disease targets to chronic hepatitis B (therapeutic) and malaria, while simultaneously showing promising results in solid tumor immuno-oncology models. I look forward to soon providing our shareholders and other interested parties with a more detailed update on our various development programs.”
Summarized financial information is attached. Further information concerning the Company’s financial position and results of operations are included in its Annual Report on Form 10-K filed with the Securities and Exchange Commission.
About GeoVax
GeoVax Labs, Inc., is a clinical-stage biotechnology company developing human vaccines against infectious diseases using its Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) vaccine platform. The Company’s development programs are focused on preventive vaccines against HIV, Zika virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa), and malaria, as well as therapeutic vaccines for chronic Hepatitis B infections and cancers. GeoVax’s vaccine platform supports in vivo production of non-infectious VLPs from the cells of the very person receiving the vaccine, mimicking a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. For more information, visit www.geovax.com.
Contact:
Robert T. McNally, Ph.D.
GeoVax Labs, Inc.
[email protected]
678-384-7220
FINANCIAL TABLES FOLLOW
| GEOVAX LABS, INC. | |||||||||||
| Condensed Consolidated Statements of Operations Information | |||||||||||
| (amounts in thousands, except per share data) | |||||||||||
| Year Ended | |||||||||||
| December 31, | |||||||||||
| 2017 | 2016 | ||||||||||
| Grant and collaboration revenue | $ | 1,075 | $ | 828 | |||||||
| Operating expenses: | |||||||||||
| Research and development | 2,017 | 1,971 | |||||||||
| General and administrative | 1,232 | 2,131 | |||||||||
| 3,249 | 4,102 | ||||||||||
| Loss from operations | (2,174 | ) | (3,274 | ) | |||||||
| Interest income | 4 | 2 | |||||||||
| Net loss | $ | (2,170 | ) | $ | (3,272 | ) | |||||
| Net loss per common share | $ | (0.03 | ) | $ | (0.08 | ) | |||||
| Weighted average shares outstanding | 68,606 | 41,517 | |||||||||
| Condensed Consolidated Balance Sheet Information | ||||||||||
| (amounts in thousands) | ||||||||||
| December 31, | ||||||||||
| 2017 | 2016 | |||||||||
| Assets: | ||||||||||
| Cash and cash equivalents | $ | 313 | $ | 454 | ||||||
| Other current assets | 135 | 90 | ||||||||
| Total current assets | 448 | 544 | ||||||||
| Property, net | 31 | 55 | ||||||||
| Other assets | 11 | 11 | ||||||||
| Total assets | $ | 490 | $ | 610 | ||||||
| Liabilities and stockholders’ equity | ||||||||||
| Current liabilities | $ | 811 | $ | 370 | ||||||
| Stockholders’ equity (deficiency) | (321 | ) | 240 | |||||||
| Total liabilities and stockholders’ equity | $ | 490 | $ | 610 | ||||||
| Common Shares Outstanding | 106,737 | 55,235 | ||||||||
